Computationally defined and in vitro validated putative genomic safe harbour loci for transgene expression in human cells

Abstract

Selection of the target site is an inherent question for any project aiming for directed transgene integration. Genomic safe harbour (GSH) loci have been proposed as safe sites in the human genome for transgene integration. Although several sites have been characterised for transgene integration in the literature, most of these do not meet criteria set out for a GSH and the limited set that do have not been characterised extensively. Here, we conducted a computational analysis using publicly available data to identify 25 unique putative GSH loci that reside in active chromosomal compartments. We validated stable transgene expression and minimal disruption of the native transcriptome in three GSH sites in vitro using human embryonic stem cells (hESCs) and their differentiated progeny. Furthermore, for easy targeted transgene expression, we have engineered constitutive landing pad expression constructs into the three validated GSH in hESCs.

Data availability

Unprocessed RNAseq FASTQ files generated for this study will be available from ENA: PRJEB49564 accession numbers: ERS16364945-ERS16364998.Custom computational scripts used for the GSH search will be available from https://github.com/foo-labHigh content imaging data will be available on Dryad.All other data generated during this study are included in the manuscript and supporting file

The following data sets were generated
The following previously published data sets were used

Article and author information

Author details

  1. Matias I Autio

    Genome Institute of Singapore, Agency for Science, Technology and Research, Singapore, Singapore
    For correspondence
    autiomi@gis.a-star.edu.sg
    Competing interests
    Matias I Autio, Patent application PCT/SG2022/050888.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-9579-9617
  2. Efthymios Motakis

    Cardiovascular Disease Translational Research Programme, National University of Singapore, Singapore, Singapore
    Competing interests
    Efthymios Motakis, Patent application PCT/SG2022/050888.
  3. Arnaud Perrin

    Genome Institute of Singapore, Agency for Science, Technology and Research, Singapore, Singapore
    Competing interests
    Arnaud Perrin, Patent application PCT/SG2022/050888.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-3545-5470
  4. Talal Bin Amin

    Genome Institute of Singapore, Agency for Science, Technology and Research, Singapore, Singapore
    Competing interests
    No competing interests declared.
  5. Zenia Tiang

    Cardiovascular Disease Translational Research Programme, National University of Singapore, Singapore, Singapore
    Competing interests
    No competing interests declared.
  6. Dang Vinh Do

    Genome Institute of Singapore, Agency for Science, Technology and Research, Singapore, Singapore
    Competing interests
    No competing interests declared.
  7. Jiaxu Wang

    Genome Institute of Singapore, Agency for Science, Technology and Research, Singapore, Singapore
    Competing interests
    No competing interests declared.
  8. Joanna Kia Min Tan

    Genome Institute of Singapore, Agency for Science, Technology and Research, Singapore, Singapore
    Competing interests
    No competing interests declared.
  9. Shirley Suet Lee Ding

    Institute of Molecular and Cell Biology, Agency for Science, Technology and Research, Singapore, Singapore
    Competing interests
    No competing interests declared.
  10. Wei Xuan Tan

    Institute of Molecular and Cell Biology, Agency for Science, Technology and Research, Singapore, Singapore
    Competing interests
    No competing interests declared.
  11. Chang Jie Mick Lee

    Cardiovascular Disease Translational Research Programme, National University of Singapore, Singapore, Singapore
    Competing interests
    No competing interests declared.
  12. Adrian KK Teo

    Institute of Molecular and Cell Biology, Agency for Science, Technology and Research, Singapore, Singapore
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-5901-7075
  13. Roger Foo

    Cardiovascular Disease Translational Research Programme, National University of Singapore, Singapore, Singapore
    For correspondence
    roger.foo@nus.edu.sg
    Competing interests
    Roger Foo, Patent application PCT/SG2022/050888.

Funding

Biomedical Research Council (1610851033)

  • Matias I Autio

Agency for Science, Technology and Research (202D8020)

  • Matias I Autio

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Reviewing Editor

  1. Tony Yuen, Icahn School of Medicine at Mount Sinai, United States

Ethics

Animal experimentation: All animal experiments were reviewed and approved ethics and animal care committees (IRB approval: A*STAR IRB 2020-096 & IACUC: 181366 and 221660).

Version history

  1. Preprint posted: December 9, 2021 (view preprint)
  2. Received: April 21, 2022
  3. Accepted: December 28, 2023
  4. Accepted Manuscript published: January 2, 2024 (version 1)
  5. Version of Record published: February 2, 2024 (version 2)

Copyright

© 2024, Autio et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 1,159
    views
  • 208
    downloads
  • 0
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Matias I Autio
  2. Efthymios Motakis
  3. Arnaud Perrin
  4. Talal Bin Amin
  5. Zenia Tiang
  6. Dang Vinh Do
  7. Jiaxu Wang
  8. Joanna Kia Min Tan
  9. Shirley Suet Lee Ding
  10. Wei Xuan Tan
  11. Chang Jie Mick Lee
  12. Adrian KK Teo
  13. Roger Foo
(2024)
Computationally defined and in vitro validated putative genomic safe harbour loci for transgene expression in human cells
eLife 13:e79592.
https://doi.org/10.7554/eLife.79592

Share this article

https://doi.org/10.7554/eLife.79592

Further reading

    1. Neuroscience
    2. Stem Cells and Regenerative Medicine
    Junjun Yao, Shaoxing Dai ... Tianqing Li
    Research Article

    While accumulated publications support the existence of neurogenesis in the adult human hippocampus, the homeostasis and developmental potentials of neural stem cells (NSCs) under different contexts remain unclear. Based on our generated single-nucleus atlas of the human hippocampus across neonatal, adult, aging, and injury, we dissected the molecular heterogeneity and transcriptional dynamics of human hippocampal NSCs under different contexts. We further identified new specific neurogenic lineage markers that overcome the lack of specificity found in some well-known markers. Based on developmental trajectory and molecular signatures, we found that a subset of NSCs exhibit quiescent properties after birth, and most NSCs become deep quiescence during aging. Furthermore, certain deep quiescent NSCs are reactivated following stroke injury. Together, our findings provide valuable insights into the development, aging, and reactivation of the human hippocampal NSCs, and help to explain why adult hippocampal neurogenesis is infrequently observed in humans.

    1. Stem Cells and Regenerative Medicine
    Magali Seguret, Patricia Davidson ... Jean-Sébastien Hulot
    Research Article

    We developed a 96-well plate assay which allows fast, reproducible, and high-throughput generation of 3D cardiac rings around a deformable optically transparent hydrogel (polyethylene glycol [PEG]) pillar of known stiffness. Human induced pluripotent stem cell-derived cardiomyocytes, mixed with normal human adult dermal fibroblasts in an optimized 3:1 ratio, self-organized to form ring-shaped cardiac constructs. Immunostaining showed that the fibroblasts form a basal layer in contact with the glass, stabilizing the muscular fiber above. Tissues started contracting around the pillar at D1 and their fractional shortening increased until D7, reaching a plateau at 25±1%, that was maintained up to 14 days. The average stress, calculated from the compaction of the central pillar during contractions, was 1.4±0.4 mN/mm2. The cardiac constructs recapitulated expected inotropic responses to calcium and various drugs (isoproterenol, verapamil) as well as the arrhythmogenic effects of dofetilide. This versatile high-throughput assay allows multiple in situ mechanical and structural readouts.